Biohaven Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BHVN in the last 30 days.
See all $BHVN insider activity →Biohaven's stock fell 13% after the FDA paused enrollment in pivotal trials for its epilepsy drug BHV-7000 due to rodent testing concerns. This is the second regulatory setback in a year. The company expects topline data from one trial later this year but may delay another. Biohaven believes the findings may not be relevant to human safety.
Biohaven (BHVN) halted a midstage study of its seizure drug, opakalim, after safety concerns. The FDA requires further assessment of potential human toxicity from a metabolite. This caused BHVN stock to drop, potentially benefiting rival Xenon.
Biohaven Pharmaceutical (BHVN) shares dropped 12% in pre-market trading after the FDA placed a partial clinical hold on its lead epilepsy drug, BHV-7000, requiring additional studies. The hold delays new patient enrollment but allows existing patients to continue treatment. The company also filed a Form 8-K with the SEC, adding to investor uncertainty. The S&P 500, Dow Jones, and Nasdaq showed minimal movement, indicating the selloff is company-specific.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BHVN (Biohaven Ltd.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent BHVN coverage spans regulation, financial news and corporate actions.
Biohaven's stock fell 13% after the FDA paused enrollment in pivotal trials for its epilepsy drug BHV-7000 due to rodent testing concerns. This is the second regulatory setback in a year. The company expects topline data from one trial later this year but may delay another. Biohaven believes the findings may not be relevant to human safety.
Negative impact expected as trial delay may delay product launch and revenue.
The hold delays enrollment and adds regulatory uncertainty, likely pressuring the stock further.
Positive enrollment progress may boost stock ahead of upcoming data releases.
Analyst downgrade likely pressures the stock lower in the short term.
AlphAI scores every news story that mentions BHVN with an AI model for sentiment and relevance, and aggregates insider trades from Biohaven Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biohaven's stock fell 13% after the FDA paused enrollment in pivotal trials for its epilepsy drug BHV-7000 due to rodent testing concerns. This is the second regulatory setback in a year. The company expects topline data from one trial later this year but may delay another. Biohaven believes the findings may not be relevant to human safety.
2 min readBiohaven (BHVN) halted a midstage study of its seizure drug, opakalim, after safety concerns. The FDA requires further assessment of potential human toxicity from a metabolite. This caused BHVN stock to drop, potentially benefiting rival Xenon.
1 min readBiohaven Pharmaceutical (BHVN) shares dropped 12% in pre-market trading after the FDA placed a partial clinical hold on its lead epilepsy drug, BHV-7000, requiring additional studies. The hold delays new patient enrollment but allows existing patients to continue treatment. The company also filed a Form 8-K with the SEC, adding to investor uncertainty. The S&P 500, Dow Jones, and Nasdaq showed minimal movement, indicating the selloff is company-specific.
2 min readBiohaven Ltd. (BHVN) shares rose 7% after hitting enrollment milestones in epilepsy and obesity trials, with data readouts expected in H2 2026. The company also began a late-stage trial for Graves' disease. BHVN has gained 47% year-to-date, with retail sentiment turning neutral.
1 min readBiohaven Pharmaceutical (BHVN) shares fell 1.9% premarket after RBC Capital downgraded the stock to Sector Perform, cutting its price target to $19 from $23. The downgrade was based on valuation following a 100% rise from 2023 lows. RBC also noted limited patient data for Biohaven's Opakalim epilepsy program. The company recently received $400M from a licensing deal with SK Biopharmaceuticals.
2 min readBiohaven (BHVN) and SK Biopharmaceuticals agreed to a $795M deal for Biohaven's epilepsy drug opakalim, with Biohaven receiving $400M upfront. Opakalim showed promising results in epilepsy studies, and the deal includes milestone payments and royalties. Biohaven will use the funds to support its pipeline, including other drug candidates. According to Biohaven, the deal allows it to monetize its pipeline through partnerships rather than public markets.
2 min readBiohaven (BHVN) announced a global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, including opakalim for focal epilepsy. The stock has seen significant gains, with a 90-day return of 52.12% and a year-to-date return of 42.16%. However, it trades at a high price-to-book ratio of 190.4x, raising valuation concerns. Analysts expect Biohaven to remain unprofitable over the next 3 years, with no meaningful revenue and a net loss of $586.841m.
2 min readBiohaven Pharmaceutical (BHVN) shares fell 1.5% premarket Tuesday after BofA downgraded it to 'Underperform' and cut its price target to $11, citing risks in its epilepsy drug and competition. Short interest rose to 16.7%. The company reported progress in a Phase 3 trial for Graves' disease. BHVN shares are up 38% in 2026.
2 min readBiohaven (BHVN) shares fell 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the impact of the opakalim deal. The company received $400M in cash, extending its runway through 2028. Trading volume was 175% of average.
2 min readBiohaven (BHVN) announced a licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 ion channel platform and opakalim. The company also won a $4M damages ruling in a lawsuit. Biohaven's stock surged 16% for the week, according to S&P Global Market Intelligence.
2 min read
